A prospective, noninterventional, multicenter longitudinal study assessing patient-reported outcomes in women with locally advanced/unresectable or metastatic Breast cancer initiating treatment with Palbociclib combination therapy
Latest Information Update: 06 Jul 2021
Price :
$35 *
At a glance
- Drugs Palbociclib (Primary) ; Aromatase inhibitors; Fulvestrant
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Therapeutic Use
- 06 Jul 2021 New trial record